• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

试验内成本效益分析中缺失数据的处理:一项综述及未来建议

Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.

作者信息

Gabrio Andrea, Mason Alexina J, Baio Gianluca

机构信息

Department of Statistical Science, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK.

出版信息

Pharmacoecon Open. 2017 Jun;1(2):79-97. doi: 10.1007/s41669-017-0015-6.

DOI:10.1007/s41669-017-0015-6
PMID:29442336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5691848/
Abstract

Cost-effectiveness analyses (CEAs) alongside randomised controlled trials (RCTs) are increasingly designed to collect resource use and preference-based health status data for the purpose of healthcare technology assessment. However, because of the way these measures are collected, they are prone to missing data, which can ultimately affect the decision of whether an intervention is good value for money. We examine how missing cost and effect outcome data are handled in RCT-based CEAs, complementing a previous review (covering 2003-2009, 88 articles) with a new systematic review (2009-2015, 81 articles) focussing on two different perspectives. First, we provide guidelines on how the information about missingness and related methods should be presented to improve the reporting and handling of missing data. We propose to address this issue by means of a quality evaluation scheme, providing a structured approach that can be used to guide the collection of information, elicitation of the assumptions, choice of methods and considerations of possible limitations of the given missingness problem. Second, we review the description of the missing data, the statistical methods used to deal with them and the quality of the judgement underpinning the choice of these methods. Our review shows that missing data in within-RCT CEAs are still often inadequately handled and the overall level of information provided to support the chosen methods is rarely satisfactory.

摘要

成本效益分析(CEA)与随机对照试验(RCT)一起,越来越多地被设计用于收集资源使用情况和基于偏好的健康状况数据,以进行医疗技术评估。然而,由于这些测量数据的收集方式,它们容易出现数据缺失的情况,这最终可能会影响关于某项干预措施是否物有所值的决策。我们研究了在基于RCT的CEA中如何处理缺失的成本和效果结果数据,通过一项新的系统评价(涵盖2009 - 2015年,81篇文章)从两个不同角度对之前的一项综述(涵盖2003 - 2009年,88篇文章)进行补充。首先,我们提供有关如何呈现缺失性信息及相关方法的指南,以改进缺失数据的报告和处理。我们建议通过质量评估方案来解决这个问题,提供一种结构化方法,可用于指导信息收集、假设引出、方法选择以及对给定缺失性问题可能局限性的考量。其次,我们回顾了对缺失数据的描述、用于处理这些数据的统计方法以及支撑这些方法选择的判断质量。我们的综述表明,RCT内CEA中的缺失数据仍然常常处理不当,为支持所选方法提供的信息总体水平很少令人满意。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/e2bf8607ca93/41669_2017_15_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/893772b966b9/41669_2017_15_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/2414c9cc434e/41669_2017_15_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/5d4cff8b5b3e/41669_2017_15_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/5287a19940df/41669_2017_15_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/e2bf8607ca93/41669_2017_15_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/893772b966b9/41669_2017_15_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/2414c9cc434e/41669_2017_15_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/5d4cff8b5b3e/41669_2017_15_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/5287a19940df/41669_2017_15_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc1/5691848/e2bf8607ca93/41669_2017_15_Fig5_HTML.jpg

相似文献

1
Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.试验内成本效益分析中缺失数据的处理:一项综述及未来建议
Pharmacoecon Open. 2017 Jun;1(2):79-97. doi: 10.1007/s41669-017-0015-6.
2
A Scoping Review of Item-Level Missing Data in Within-Trial Cost-Effectiveness Analysis.在临床试验内成本效益分析中项目水平缺失数据的范围综述。
Value Health. 2022 Sep;25(9):1654-1662. doi: 10.1016/j.jval.2022.02.009. Epub 2022 Mar 24.
3
A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.随机对照试验中成本效益分析中缺失数据处理指南。
Pharmacoeconomics. 2014 Dec;32(12):1157-70. doi: 10.1007/s40273-014-0193-3.
4
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.综合护理路径在医疗环境中对成人和儿童的有效性:一项系统评价。
JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001.
5
Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.在患者层面的成本效益分析中与随机临床试验一起处理缺失数据。
Appl Health Econ Health Policy. 2005;4(2):65-75. doi: 10.2165/00148365-200504020-00001.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.心肌梗死后心力衰竭中醛固酮拮抗剂的临床疗效和成本效果的系统评价和经济评估。
Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240.
8
Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials.随机对照试验中参与者和专业人员偏好影响的概念框架与系统评价
Health Technol Assess. 2005 Sep;9(35):1-186, iii-iv. doi: 10.3310/hta9350.
9
Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders预防和治疗精神、神经及物质使用障碍的干预措施、政策和平台的成本效益及可负担性
10
Reporting missing participant data in randomised trials: systematic survey of the methodological literature and a proposed guide.随机试验中缺失参与者数据的报告:方法学文献的系统综述及拟议指南
BMJ Open. 2015 Dec 30;5(12):e008431. doi: 10.1136/bmjopen-2015-008431.

引用本文的文献

1
Poor reporting quality and high proportion of missing data in economic evaluations alongside pragmatic trials: a cross-sectional survey.实用试验中经济评估的报告质量差及数据缺失比例高:一项横断面调查
BMC Med Res Methodol. 2025 Mar 6;25(1):61. doi: 10.1186/s12874-025-02519-z.
2
Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.Ⅲ期腹股沟淋巴结转移黑色素瘤患者腹股沟与髂腹股沟淋巴结清扫术的经济学评价:来自EAGLE FM随机试验的证据
Ann Surg Oncol. 2025 Jun;32(6):4211-4222. doi: 10.1245/s10434-025-17040-2. Epub 2025 Feb 27.
3

本文引用的文献

1
Incremental Net Benefit of Early Intervention for Preschool-Aged Children with Emotional and Behavioral Problems in Foster Care.寄养中患有情绪和行为问题的学龄前儿童早期干预的增量净效益
Child Youth Serv Rev. 2014 Jan;36:213-219. doi: 10.1016/j.childyouth.2013.11.025. Epub 2013 Dec 5.
2
The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature.随机对照试验出版物中八种广泛使用的患者报告结局测量工具(PROMs)中处理和报告缺失结局数据的当前做法:当前文献综述
Qual Life Res. 2016 Jul;25(7):1613-23. doi: 10.1007/s11136-015-1206-1. Epub 2016 Jan 28.
3
Emerging burden of post-cancer therapy complications on unplanned hospitalisation and costs among Australian cancer patients: a retrospective cohort study over 14 years.
澳大利亚癌症患者中癌症治疗后并发症对非计划住院和费用的新负担:一项为期14年的回顾性队列研究
Sci Rep. 2025 Feb 8;15(1):4709. doi: 10.1038/s41598-025-89247-y.
4
Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration.评估孟加拉国癌症幸存者在全身治疗和放射治疗期间的健康相关生活质量:癌症特异性探索。
BMC Cancer. 2023 Dec 7;23(1):1208. doi: 10.1186/s12885-023-11670-z.
5
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations.处理健康经济学和结果研究(HEOR)中的缺失数据:系统评价和实用建议。
Pharmacoeconomics. 2023 Dec;41(12):1589-1601. doi: 10.1007/s40273-023-01297-0. Epub 2023 Jul 25.
6
Conducting Trial-Based Economic Evaluations Using R: A Tutorial.使用R进行基于试验的经济评估:教程
Pharmacoeconomics. 2023 Nov;41(11):1403-1413. doi: 10.1007/s40273-023-01301-7. Epub 2023 Jul 17.
7
Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study.西班牙急性冠脉综合征患者参与 U-PGx PREPARE 研究的药物基因组指导抗血小板治疗的经济学评价。
Hum Genomics. 2023 Jun 7;17(1):51. doi: 10.1186/s40246-023-00495-3.
8
The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?基于试验的经济评估中缺失数据的处理:在进行纵向线性混合模型分析之前,是否应该对数据进行多次插补?
Eur J Health Econ. 2023 Aug;24(6):951-965. doi: 10.1007/s10198-022-01525-y. Epub 2022 Sep 26.
9
Human and economic impacts of natural disasters: can we trust the global data?自然灾害对人类和经济的影响:我们能相信全球数据吗?
Sci Data. 2022 Sep 16;9(1):572. doi: 10.1038/s41597-022-01667-x.
10
A scoping review of statistical methods for trial-based economic evaluations: The current state of play.基于试验的经济学评价中统计方法的范围综述:现状。
Health Econ. 2022 Dec;31(12):2680-2699. doi: 10.1002/hec.4603. Epub 2022 Sep 11.
Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.
在随机试验的同时进行经济评估:当前的方法学问题与新方法
Pharmacoeconomics. 2016 May;34(5):447-61. doi: 10.1007/s40273-015-0371-y.
4
Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer.癌症患者合并重度抑郁症的综合协作护理的成本效益
J Psychosom Res. 2015 Dec;79(6):465-70. doi: 10.1016/j.jpsychores.2015.10.012. Epub 2015 Nov 9.
5
(Cost-)effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT.慢性阻塞性肺疾病患者急性加重自我治疗的(成本)效益:一项随机对照试验的2年随访
Respirology. 2016 Apr;21(3):497-503. doi: 10.1111/resp.12697. Epub 2015 Dec 9.
6
Cost-effectiveness analysis of a continuing care intervention for cocaine-dependent adults.针对可卡因成瘾成年患者的持续护理干预措施的成本效益分析。
Drug Alcohol Depend. 2016 Jan 1;158:38-44. doi: 10.1016/j.drugalcdep.2015.10.032. Epub 2015 Nov 12.
7
The cost-effectiveness of short-term and long-term psychotherapy in the treatment of depressive and anxiety disorders during a 5-year follow-up.短期和长期心理治疗在5年随访期间治疗抑郁和焦虑症的成本效益。
J Affect Disord. 2016 Jan 15;190:254-263. doi: 10.1016/j.jad.2015.09.065. Epub 2015 Oct 24.
8
Clinical effectiveness and cost-effectiveness of open and arthroscopic rotator cuff repair [the UK Rotator Cuff Surgery (UKUFF) randomised trial].开放性与关节镜下肩袖修复术的临床疗效及成本效益[英国肩袖手术(UKUFF)随机试验]
Health Technol Assess. 2015 Oct;19(80):1-218. doi: 10.3310/hta19800.
9
Training mental health professionals in suicide practice guideline adherence: Cost-effectiveness analysis alongside a randomized controlled trial.对心理健康专业人员进行自杀实践指南遵循方面的培训:成本效益分析与一项随机对照试验同步进行。
J Affect Disord. 2015 Nov 1;186:203-10. doi: 10.1016/j.jad.2015.07.028. Epub 2015 Jul 26.
10
Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial).住院成年患者有症状输尿管结石管理中药物治疗的应用:一项多中心、安慰剂对照、随机对照试验以及钙通道阻滞剂(硝苯地平)和α受体阻滞剂(坦索罗辛)的成本效益分析(SUSPEND试验)
Health Technol Assess. 2015 Aug;19(63):vii-viii, 1-171. doi: 10.3310/hta19630.